RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer

BackgroundCombined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy significantly improve the outcome of patients with advanced estrogen receptor-positive (ER+) breast cancer. However, resistance to this treatment and disease progression remains a major clinical challenge. High expression of the rec...

Full description

Saved in:
Bibliographic Details
Main Authors: Charlotte K. Kindt, Sidse Ehmsen, Sofie Traynor, Benedetta Policastro, Nikoline Nissen, Mie K. Jakobsen, Monique F. Hundebøl, Lene E. Johansen, Martin Bak, Elsa Arbajian, Johan Staaf, Henrik J. Ditzel, Carla L. Alves
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1497093/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832585037776683008
author Charlotte K. Kindt
Sidse Ehmsen
Sidse Ehmsen
Sidse Ehmsen
Sofie Traynor
Benedetta Policastro
Nikoline Nissen
Mie K. Jakobsen
Monique F. Hundebøl
Lene E. Johansen
Martin Bak
Elsa Arbajian
Johan Staaf
Henrik J. Ditzel
Henrik J. Ditzel
Henrik J. Ditzel
Carla L. Alves
author_facet Charlotte K. Kindt
Sidse Ehmsen
Sidse Ehmsen
Sidse Ehmsen
Sofie Traynor
Benedetta Policastro
Nikoline Nissen
Mie K. Jakobsen
Monique F. Hundebøl
Lene E. Johansen
Martin Bak
Elsa Arbajian
Johan Staaf
Henrik J. Ditzel
Henrik J. Ditzel
Henrik J. Ditzel
Carla L. Alves
author_sort Charlotte K. Kindt
collection DOAJ
description BackgroundCombined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy significantly improve the outcome of patients with advanced estrogen receptor-positive (ER+) breast cancer. However, resistance to this treatment and disease progression remains a major clinical challenge. High expression of the receptor tyrosine kinase REarranged during Transfection (RET) has been associated with resistance to endocrine therapy in breast cancer, but the role of RET in CDK4/6i treatment response/resistance remains unexplored.MethodsTo identify gene expression alterations associated with resistance to combined endocrine therapy and CDK4/6i, we performed RNA sequencing of two ER+ breast cancer cell models resistant to this combined therapy. The functional role of RET was assessed by siRNA-mediated RET silencing and targeted inhibition with the FDA/EMA-approved RET-selective inhibitor selpercatinib in resistant breast cancer cells and patient-derived organoids (PDOs). RET silencing was evaluated mechanistically using global gene expression and pathway analysis. The clinical relevance of RET expression in ER+ breast cancer was investigated by gene array analysis of primary tumors treated with endocrine therapy and by immunohistochemical scoring of metastatic lesions from patients who received combined CDK4/6i and endocrine therapy.ResultsWe show that RET is upregulated in ER+ breast cancer cell lines resistant to combined CDK4/6i and fulvestrant compared to isogenic cells resistant to fulvestrant alone. siRNA-mediated silence of RET in high RET-expressing, combined CDK4/6i- and fulvestrant-resistant cells reduced their growth partially by affecting cell cycle regulators of the G2-M phase and E2F targets. Notably, targeting RET with selpercatinib in combination with CDK4/6i inhibited the growth of CDK4/6i-resistant cell lines and resensitized ER+ breast cancer patient-derived organoids resistant to CDK4/6i. Finally, analysis of RET expression in ER+ breast cancer patients treated with endocrine therapy showed that high RET expression correlated with poor clinical outcomes. We further observed a shorter median survival to combined CDK4/6i and endocrine therapy in patients with RET-positive compared to RET-negative tumors, but this difference did not reach statistical significance.ConclusionsOur findings show that RET is overexpressed in ER+ metastatic breast cancer resistant to combined CDK4/6i and endocrine therapy, rendering RET inhibition a promising therapeutic approach for patients who experience disease progression on combined CDK4/6i and endocrine therapy.
format Article
id doaj-art-f6678566e7304a6384e1de32ca408baa
institution Kabale University
issn 2234-943X
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj-art-f6678566e7304a6384e1de32ca408baa2025-01-27T06:40:14ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14970931497093RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancerCharlotte K. Kindt0Sidse Ehmsen1Sidse Ehmsen2Sidse Ehmsen3Sofie Traynor4Benedetta Policastro5Nikoline Nissen6Mie K. Jakobsen7Monique F. Hundebøl8Lene E. Johansen9Martin Bak10Elsa Arbajian11Johan Staaf12Henrik J. Ditzel13Henrik J. Ditzel14Henrik J. Ditzel15Carla L. Alves16Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DenmarkDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DenmarkDepartment of Oncology, Odense University Hospital, Odense, DenmarkInstitute of Clinical Research, University of Southern Denmark, Odense, DenmarkDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DenmarkDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DenmarkDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DenmarkDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DenmarkDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DenmarkDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DenmarkDepartment of Pathology, Sydvestjysk Sygehus, Esbjerg, DenmarkDivision of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, SwedenDivision of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, SwedenDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DenmarkDepartment of Oncology, Odense University Hospital, Odense, DenmarkInstitute of Clinical Research, University of Southern Denmark, Odense, DenmarkDepartment of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, DenmarkBackgroundCombined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy significantly improve the outcome of patients with advanced estrogen receptor-positive (ER+) breast cancer. However, resistance to this treatment and disease progression remains a major clinical challenge. High expression of the receptor tyrosine kinase REarranged during Transfection (RET) has been associated with resistance to endocrine therapy in breast cancer, but the role of RET in CDK4/6i treatment response/resistance remains unexplored.MethodsTo identify gene expression alterations associated with resistance to combined endocrine therapy and CDK4/6i, we performed RNA sequencing of two ER+ breast cancer cell models resistant to this combined therapy. The functional role of RET was assessed by siRNA-mediated RET silencing and targeted inhibition with the FDA/EMA-approved RET-selective inhibitor selpercatinib in resistant breast cancer cells and patient-derived organoids (PDOs). RET silencing was evaluated mechanistically using global gene expression and pathway analysis. The clinical relevance of RET expression in ER+ breast cancer was investigated by gene array analysis of primary tumors treated with endocrine therapy and by immunohistochemical scoring of metastatic lesions from patients who received combined CDK4/6i and endocrine therapy.ResultsWe show that RET is upregulated in ER+ breast cancer cell lines resistant to combined CDK4/6i and fulvestrant compared to isogenic cells resistant to fulvestrant alone. siRNA-mediated silence of RET in high RET-expressing, combined CDK4/6i- and fulvestrant-resistant cells reduced their growth partially by affecting cell cycle regulators of the G2-M phase and E2F targets. Notably, targeting RET with selpercatinib in combination with CDK4/6i inhibited the growth of CDK4/6i-resistant cell lines and resensitized ER+ breast cancer patient-derived organoids resistant to CDK4/6i. Finally, analysis of RET expression in ER+ breast cancer patients treated with endocrine therapy showed that high RET expression correlated with poor clinical outcomes. We further observed a shorter median survival to combined CDK4/6i and endocrine therapy in patients with RET-positive compared to RET-negative tumors, but this difference did not reach statistical significance.ConclusionsOur findings show that RET is overexpressed in ER+ metastatic breast cancer resistant to combined CDK4/6i and endocrine therapy, rendering RET inhibition a promising therapeutic approach for patients who experience disease progression on combined CDK4/6i and endocrine therapy.https://www.frontiersin.org/articles/10.3389/fonc.2024.1497093/fullestrogen receptor-positive breast cancerRETselpercatinibCDK4/6 inhibitordrug resistance
spellingShingle Charlotte K. Kindt
Sidse Ehmsen
Sidse Ehmsen
Sidse Ehmsen
Sofie Traynor
Benedetta Policastro
Nikoline Nissen
Mie K. Jakobsen
Monique F. Hundebøl
Lene E. Johansen
Martin Bak
Elsa Arbajian
Johan Staaf
Henrik J. Ditzel
Henrik J. Ditzel
Henrik J. Ditzel
Carla L. Alves
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
Frontiers in Oncology
estrogen receptor-positive breast cancer
RET
selpercatinib
CDK4/6 inhibitor
drug resistance
title RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
title_full RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
title_fullStr RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
title_full_unstemmed RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
title_short RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
title_sort ret inhibition overcomes resistance to combined cdk4 6 inhibitor and endocrine therapy in er breast cancer
topic estrogen receptor-positive breast cancer
RET
selpercatinib
CDK4/6 inhibitor
drug resistance
url https://www.frontiersin.org/articles/10.3389/fonc.2024.1497093/full
work_keys_str_mv AT charlottekkindt retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT sidseehmsen retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT sidseehmsen retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT sidseehmsen retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT sofietraynor retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT benedettapolicastro retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT nikolinenissen retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT miekjakobsen retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT moniquefhundebøl retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT leneejohansen retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT martinbak retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT elsaarbajian retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT johanstaaf retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT henrikjditzel retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT henrikjditzel retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT henrikjditzel retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer
AT carlalalves retinhibitionovercomesresistancetocombinedcdk46inhibitorandendocrinetherapyinerbreastcancer